Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Sector Deal
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $116.00 price target on Kymera Therapeutics (NASDAQ: KYMR) after AbbVie ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
